Emtricitabine/Tenofovir Alafenamide (Descovy)

The Latest

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Renal Upsides for Tenofovir Alafenamide

E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.

By Barbara Jungwirth and Myles Helfand

Descovy Approved in Canada -- Key Information

On April 29, 2016, Health Canada licensed the sale and use of a new fixed-dose combination of two anti-HIV drugs sold under the brand name Descovy.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Descovy, New HIV Drug Containing Tenofovir Alafenamide, Approved by FDA

Descovy (emtricitabine/tenofovir alafenamide) is the third approved HIV drug to include tenofovir alafenamide (TAF), which has been shown to have better bone and kidney safety than its predecessor tenofovir disoproxil fumarate (TDF, Viread).

By Warren Tong

FDA Approves Descovy, an Updated Version of Truvada -- But Not for PrEP

The FDA has approved Descovy, Gilead Sciences' latest combination pill containing emtricitabine and an updated version of tenofovir.

By Liz Highleyman for BETA